Aptevo Therapeutics reports strong remission rates in AML patients using mipletamig plus ven/aza, with Cohort 2 enrollment ...
Symptomatic cerebral cavernous malformation is a rare disease, and affected individuals are at risk of strokes due to intracerebral haemorrhage or new non-haemorrhagic neurological deficits.
In this trial, the efficacy and safety of the therapy were evaluated against a sham control in treatment-naïve SMA Type 2 ...
In an early-stage clinical trial, the therapy nearly doubled the expected survival time of young patients. Still, experts ...
Polen Capital, an investment management company, released its “Polen Global Growth Strategy” fourth-quarter 2024 investor ...
Current FDA approval of this adaptive system is for the treatment of Parkinson’s only, not essential tremor, dystonia (a ...